Nitroxoline, 50 mg 50 pcs.

Nitroxoline is a broad-spectrum antimicrobial and antiprotozoal drug for the treatment of urinary tract infections.

Nitroxoline selectively inhibits the synthesis of bacterial DNA, forms complexes with metal-containing enzymes of the microbial cell and acts both on Gram-positive microorganisms: Staphylococcus spp. (including S.aureus), Streptococcus spp. (including beta-haemolytic streptococci, Streptococcus pneumoniae, Enterococcus faecalis), Corynebacterium spp, Bacillus subtilis; and on Gram-negative microorganisms: N.gonorrhoeae, E.coli, Proteus spp., Klebsiella spp., Salmonella spp., Shigella spp., Enterobacter spp.

Nitroxoline is also active against Mycobacterium tuberculosis, Trichomonas vaginalis, some types of fungi (Candida spp., dermatophytes, molds, some deep mycosis agents).

Pharmacokinetics

Nitroxoline is well absorbed from the digestive tract after oral administration. It is excreted mainly by the kidneys unchanged. After a single dose of 100 mg of the drug the minimum bacteriostatic concentration in the urine is retained up to 3 hours, after 400 mg – up to 7 hours.

Indications

acute, chronic and recurrent infections of the genitourinary system caused by microorganisms sensitive to nitroxoline: pyelonephritis, cystitis, urethritis, epididymitis, infected adenoma or prostate carcinoma;

prevention of infectious complications in the postoperative period during surgical interventions on the kidneys and genitourinary tract, as well as during diagnostic and therapeutic procedures (catheterization, cystoscopy, after operations on the kidneys and urinary tract);

prevention of recurrent urinary tract infections.

Pharmacological effect

Nitroxoline is a broad-spectrum antimicrobial and antiprotozoal drug for the treatment of urinary tract infections.

Nitroxoline selectively inhibits the synthesis of bacterial DNA, forms complexes with metal-containing enzymes of the microbial cell and acts both on gram-positive microorganisms: Staphylococcus spp. (including S.aureus), Streptococcus spp. (including beta-hemolytic streptococci, Streptococcus pneumoniae, Enterococcus faecalis), Corynebacterium spp., Bacillus subtilis; and for gram-negative microorganisms: N.gonorrhoeae, E.coli, Proteus spp., Klebsiella spp., Salmonella spp., Shigella spp., Enterobacter spp.

Nitroxoline is also active against Mycobacterium tuberculosis, Trichomonas vaginalis, some types of fungi (Candida spp., dermatophytes, molds, some pathogens of deep mycoses).

Pharmacokinetics

After oral administration, nitroxoline is well absorbed from the digestive tract. It is excreted primarily by the kidneys unchanged. With a single dose of 100 mg of the drug, the minimum bacteriostatic concentration in the urine lasts up to 3 hours, after taking 400 mg – up to 7 hours.

Special instructions

During treatment, the urine turns saffron yellow.

Active ingredient

Nitroxoline

Composition

active ingredient: nitroxoline – 50.00 mg;

excipients (core): lactose monohydrate – 18.80 mg, potato starch – 26.00 mg, colloidal silicon dioxide – 0.60 mg, talc – 2.80 mg, calcium stearate – 0.90 mg, polysorbate-80 (Tween-80) – 0.90 mg;

excipients (shell): sucrose – 83.13 mg, magnesium hydroxycarbonate – 10.77 mg, povidone K17 – 1.66 mg, colloidal silicon dioxide – 0.81 mg, talc – 0.30 mg, titanium dioxide – 2.82 mg, tropeolin dye 0 – 0.18 mg, azorubine dye (acid red 2C for pharmaceutical purposes) – 0.03 mg, beeswax – 0.30 mg.

Contraindications

Hypersensitivity (including to other 8-hydroxyquinoline derivatives), renal dysfunction, accompanied by oliguria, anuria; severe liver diseases, cataracts, neuritis, polyneuritis, glucose-6-phosphate dehydrogenase deficiency, pregnancy, breastfeeding.

Side Effects

Dyspepsia (nausea, vomiting), loss of appetite, allergic reactions (skin rash); tachycardia, ataxia, headache, paresthesia, polyneuropathy, liver dysfunction.

Interaction

When Nitroxoline is used together with drugs of the tetracycline group, a summation of the effects of each drug is observed, with nystatin and levorin – a potentiation of the effect.

To avoid the summation of the negative neurotropic effect, Nitroxoline should not be combined with nitrofurans.

Storage conditions

In a dry place, protected from light

Shelf life

4 years

Manufacturer

Irbitsky Chemical Plant, Russia